Page last updated: 2024-08-21

azomycin and pa 824

azomycin has been researched along with pa 824 in 178 studies

Research

Studies (178)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	31 (17.42)	29.6817
2010's	97 (54.49)	24.3611
2020's	50 (28.09)	2.80

Authors

Authors	Studies
Anderson, SW; Arain, TM; Baker, WR; Barry, CE; Kreiswirth, BN; Langhorne, MH; McMurray, DN; Sherman, DR; Stover, CK; Towell, JA; VanDevanter, DR; Warrener, P; Yuan, Y	1
Bae, YM; Bair, TB; Choi, KP; Daniels, L	1
Choi, KP; Daniels, L; Kendrick, N	1
Doi, N	1
Bishai, W; Grosset, J; Lounis, N; Nuermberger, E; Rosenthal, I; Tyagi, S; Williams, K; Yoshimatsu, T	1
Driscoll, DK; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Reynolds, RC; Rose, JD; Tompkins, NM	1
Ahmad, K	1
Albert, TJ; Barry, CE; Boshoff, H; Daniels, L; Dick, T; Dowd, CS; Manjunatha, UH; Norton, JE; Pang, SS; Zhang, L	1
Andries, K; Chauffour, A; Jarlier, V; Ji, B	1
Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C	1
Almeida, D; Bishai, WR; Grosset, JH; Nuermberger, E; Peloquin, CA; Rosenthal, I; Tyagi, S; Williams, KN	1
Barry, CE; Dowd, CS; Krahenbuhl, JL; Lahiri, R; Manjunatha, UH; Randhawa, B	1
Bloomer, WD; McNeil, MR; Papadopoulou, MV	1
Zhang, Y	1
Coates, AR; Hu, Y; Mitchison, DA	1
Almeida, D; Grosset, JH; Nuermberger, E; Rosenthal, I; Tasneen, R; Tyagi, S; Williams, KN	1
Barry, CE; Dowd, CS; Goodwin, MB; Keller, TH; Knox, JE; Li, X; Lipinski, CA; Manjunatha, UH	1
Baker, EN; Bashiri, G; Moreland, NJ; Squire, CJ	1
Nau, JY	1
Anderson, RF; Boyd, M; Denny, WA; Maroz, A; Palmer, BD; Shinde, SS	1
Mancera, RL; Rivers, EC	1
Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K	1
Nathan, C	1
Barry, CE; Boshoff, HI; Dowd, CS; Ha, YH; Jiricek, J; Kang, S; Keller, TH; Kim, P; Ledwidge, R; Lee, IY; Manjunatha, U; Niyomrattanakit, P; Singh, R; Zhang, L	1
Anderson, RF; Blaser, A; Denny, WA; Franzblau, SG; Ma, Z; Palmer, BD; Shinde, SS; Thompson, AM	1
Edwards, DA; Elbert, KJ; Garcia-Contreras, L; Hickey, AJ; Peloquin, CA; Sung, JC; Verberkmoes, JL	1
Ginsberg, AM; Laurenzi, MW; Rouse, DJ; Spigelman, MK; Whitney, KD	2
Blaser, A; Denny, WA; Franzblau, SG; Kmentova, I; Ma, Z; Palmer, BD; Sutherland, HS; Thompson, AM; Wan, B; Wang, Y	5
Anderson, RF; Denny, WA; Franzblau, SG; Ma, Z; Maroz, A; Palmer, BD; Shinde, SS	1
Edwards, DA; Elbert, KJ; Garcia-Contreras, L; Hickey, AJ; Muttil, P; Padilla, D; Sung, JC; Telko, M; Verberkmoes, JL	1
Dawson, R; Diacon, AH; Donald, PR; Ginsberg, AM; Hanekom, M; Laurenzi, MW; Maritz, SJ; Narunsky, K; Rouse, DJ; Spigelman, MK; van Niekerk, C; Venter, A; Whitney, K	1
Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M	1
Marsini, MA; Reider, PJ; Sorensen, EJ	1
Ahmad, Z; Derendorf, H; Ginsberg, A; Grosset, JH; Nuermberger, EL; Peloquin, CA; Singh, RP; Tyagi, S	1
Anderson, RF; Baker, EN; Bashiri, G; Denny, WA; Dogra, M; Helsby, NA; O'Toole, R; Palmer, BD; Shinde, SS; Tingle, MD	1
Hutson, S	1
Barry, CE; Bollo, S; Boshoff, HI; Dowd, CS; Kang, S; Núñez-Vergara, LJ; Squella, JA; Zhang, L	1
Denny, WA; Palmer, BD	1
Degani, MS; Tawari, NR	1
Barry, CE; Boshoff, HI; Cherian, J; Choi, I; Dartois, V; Dick, T; Goodwin, M; Ha, YH; Jiricek, J; Keller, TH; Lakshminarayana, SB; Lee, YS; Manjunatha, UH; Mukherjee, T; Nayyar, A; Niyomrattanakit, P; Ravindran, S; Singh, R	1
Ginsberg, A	1
Cui, Z; Fu, X; Hu, Z; Jin, K; Li, Y; Wu, W; Yu, G; Zhang, L	1
Archer, JA; Baù, D; Feuerriegel, S; Köser, CU; Marti-Renom, MA; Niemann, S; Rüsch-Gerdes, S; Summers, DK	1
Andries, K; Li, SY; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Tasneen, R; Taylor, D; Williams, KN	1
Barry, CE; Boshoff, HI; Cherian, J; Dick, T; Dowd, CS; Gurumurthy, M; Lee, YS; Manjunatha, UH; Mukherjee, T; Nayyar, A; Niyomrattanakit, P; Singh, R; Tay, JA	1
Bishai, WR; Davis, SL; Harper, J; Jain, SK; Kramnik, I; Nuermberger, EL; Pomper, MG; Skerry, C; Tasneen, R; Weir, M	1
Campbell, S; Jakubiec, W; Ladutko, L; Miller, PF; Mitton-Fry, M; Paige, D; Silvia, A; Wallis, RS	1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; du Bois, J; Erondu, N; Ginsberg, AM; Narunsky, K; Spigelman, MK; van Niekerk, C; Venter, A	1
Roehr, B	1
Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K	1
Campos-Rivera, MP; Cole, ST; Gonzalez-Martinez, NA; Ocampo-Candiani, J; Vera-Cabrera, L	1
Becker, P; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Mendel, CM; Spigelman, MK; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F; Winter, H	1
Kmietowicz, Z	1
Cole, ST; Hartkoorn, RC; Lechartier, B	1
Dawson, R; Diacon, A	1
Egizi, E; Erondu, N; Everitt, D; Ginsberg, A; Pauli, E; Rouse, DJ; Severynse-Stevens, D; Winter, H	1
Alsultan, A; Belchis, DA; Dutta, NK; Gniadek, TJ; Karakousis, PC; Mdluli, KE; Nuermberger, EL; Peloquin, CA; Pinn, ML	1
Egizi, E; Erondu, N; Everitt, D; Ginsberg, A; Pauli, E; Whitney, K; Winter, H	1
Anand, RS; Paramasivan, CN; Somasundaram, S; Venkatesan, P	1
Mukhopadhyay, B; Purwantini, E	1
Jeong, BH; Koh, WJ; Kwon, YS	1
Garcia-Prats, AJ; Hesseling, AC; Schaaf, HS; Seddon, JA	1
Diao, C; Liang, L; Liu, X; Wang, L; Xu, Y; Zhang, J; Zhang, S	1
Allen, R; Aweeka, F; Bao, J; Cramer, Y; Dooley, KE; Haas, DW; Koletar, SL; Luetkemeyer, AF; Marzan, F; Murray, S; Park, JG; Savic, R; Sutherland, D	1
Barry, CE; Blasco, F; Boshoff, HI; Cherian, J; Dick, T; Goh, A; Gurumurthy, M; Ho, PC; Jiricek, J; Lakshminarayana, SB; Manjunatha, UH; Nanjundappa, M; Nayyar, A; Ravindran, S; Singh, R	1
Dutta, NK; Karakousis, PC	1
Cho, S; Franzblau, SG; Kim, Y; Lu, Y; Ma, Z; Mdluli, K; Upton, AM; Wang, B; Wang, Y; Xu, J; Yang, TJ	1
Amoabeng, O; Mdluli, KE; Minkowski, A; Nuermberger, EL; Tasneen, R; Upton, AM; Williams, K	1
Chang, KC; Heyckendorf, J; Lange, C; Olaru, ID; von Groote-Bidlingmaier, F; Yew, WW	1
Burger, DA; Dawson, R; Diacon, AH; Donald, PR; Everitt, D; Hutchings, J; Mendel, CM; Schall, R; Symons, G; van Niekerk, C; Venter, A; von Groote-Bidlingmaier, F	1
Gund, MG; Mangu, NK; Nair, V; Okello, MO; Seo, BI	1
Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F	1
Migliori, GB; Sotgiu, G	1
A Bester, L; Bratkowska, D; Govender, T; Kruger, HG; Maguire, GE; Shobo, A; Singh, S	1
Inturi, B; Pujar, GV; Purohit, MN	1
Bifani, P; Chua, A; Ghode, P; Haver, HL; Lakshminarayana, SB; Mathema, B; Singhal, A; Wintjens, R	1
Arora, G; Kang, YG; Lee, IY; Park, CY; Shin, H; Singh, R; Yu, CM	1
Baijnath, S; Bester, LA; Bratkowska, D; Govender, T; Kruger, HG; Naicker, T; Naiker, S; Shobo, A; Singh, SD; Somboro, AM	1
Ballinger, E; Glasheen, J; Gold, B; Ling, Y; Nathan, C; Quezada, LL; Roberts, J; Somersan-Karakaya, S; Warren, JD; Warrier, T	1
Franzblau, SG; Gutka, HJ; Movahedzadeh, F; Wang, Y	1
Betoudji, F; Converse, PJ; Dartois, V; Li, SY; Mdluli, KE; Mendel, CM; Nuermberger, EL; Tasneen, R; Tyagi, S; Williams, K; Yang, T	1
Duan, H; Liang, L; Liu, X; Ma, Y; Wang, L; Wang, Q; Yao, J; Zhang, R; Zhang, S; Zhou, X	1
Bruhn, DF; Lee, RE; Lenaerts, AJ; Liu, J; Scherman, MS; Singh, AP; Yang, L	1
Das, SC; Krittaphol, W; Momin, MAM; Thien, SJ	1
Koniordou, M; Patterson, S; Seifert, K; Wyllie, S	1
Cohen, J	1
Mendel, C; Murray, S; Spigelman, M	1
Anderson, RF; Blaser, A; Chatelain, E; Denny, WA; Franzblau, SG; Launay, D; Ma, Z; Maes, L; Palmer, BD; Shinde, SS; Thompson, AM; Wan, B; Wang, Y	1
Ahmed, Z; Bhagat, A; Kour, G; Singh, PP	1
Converse, PJ; Li, SY; Mdluli, K; Nuermberger, EL; Soni, H; Tasneen, R; Tyagi, S	1
Li, DG; Ren, ZX	1
Alland, D; Bajaj, A; Dhiman, R; Gosain, TP; Hwang, YK; Jung, MG; Kidwai, S; Kumar, P; Kumar, S; Lee, IY; Mawatwal, S; Park, CY; Singh, R; Song, CS; Tiwari, P	1
Bacchi, CJ; Braillard, S; Chatelain, E; Denny, WA; Gaukel, E; Launay, D; Maes, L; Marshall, AJ; Mowbray, CE; Thompson, AM; Wring, SA; Yarlett, N	1
Connell, N; Dartois, V; Freundlich, JS; Ho, HP; Inoyama, D; Kandasamy, S; Kumar, P; Occi, J; Paget, SD; Perryman, AL; Russo, R; Singleton, E; Tuckman, M; Zimmerman, MD	1
Feng, T; Jing, J; Liu, X; Mi, L; Shen, X; Wang, L; Zhang, R; Zhang, S; Zhao, J; Zhou, N	1
Aguilar-Ayala, DA; Cnockaert, M; Gonzalez-Y-Merchand, J; Martin, A; Palomino, JC; Vandamme, P	1
Bujalska-Zadrozny, M; Pstragowski, M; Zbrzezna, M	1
Baillie, L; Baptista, R; Beckmann, M; Fazakerley, DM; Mur, LAJ	1
Lyons, MA	3
Baijnath, S; Govender, T; Kruger, HG; Makatini, MM; Naicker, T; Pamreddy, A; Shobo, A	1
Arbex, MA; D'Ambrosio, L; Dalcolmo, M; Duarte, R; Gaga, M; Migliori, GB; Munoz-Torrico, M; Rendon, A; Silva, DR; Tiberi, S; Visca, D; Zumla, A	1
Loganathan, U; Mukhopadhyay, B; Purwantini, E	1
Chaudhari, HK; Pahelkar, A	1
Borkute, R; Choudhari, AS; Degani, MS; Krishna, VS; Mali, HM; Sabale, SS; Sarkar, D; Sriram, D	1
de Miranda Silva, C; Drusano, GL; Hajihosseini, A; Louie, A; Myrick, J; Nole, J; Schmidt, S	1
Ang, CW; Avery, VM; Blaskovich, MAT; Butler, MS; Cooper, MA; Debnath, A; Hahn, HJ; Jarrad, AM; Jones, AJ; Karoli, T; Pelingon, R; Sykes, ML; Tan, L; West, NP; Woods, K	1
Laughon, BE; Lee, SFK; Lipman, M; McHugh, TD	1
Chu, N; Huang, H; Jing, W; Pang, Y; Shang, Y; Wang, F; Wen, S; Xue, Y; Zhang, T; Zong, Z	1
Fattorini, L; Giannoni, F; Iacobino, A; Pardini, M; Piccaro, G	1
Del Parigi, A; Everitt, D; Li, H; Li, M; Mendel, C; Nedelman, JR; Salinger, DH	1
Billard, T; Dickson, C; Gampe, CM; Ghiazza, C; Tlili, A	1
Ceyssens, PJ; Coppee, JY; Legendre, R; Mathys, V; Sismeiro, O; Sury, A; Van den Bossche, A; Varet, H	1
Everitt, D; Nedelman, JR; Salinger, DH; Subramoney, V	1
Dheda, K; Dooley, KE; Furin, J; Gumbo, T; Maartens, G; Murray, M; Nardell, EA; Warren, RM	1
Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S	1
Burki, T	1
Keam, SJ	1
Mushtaq, A	1
Bendet, P; Berg, A; Cirrincione, K; Deshpande, D; Gumbo, T; Hanna, D; Hermann, D; Magombedze, G; Martin, K; Romero, K; Srivastava, S; van Zyl, J	1
Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E	1
Furin, J; McKenna, L	1
Aher, RB; Sarkar, D	1
Afriat-Jurnou, L; Ahmed, FH; Almeida, DV; Aung, HL; Beatson, SA; Cook, GM; Forde, BM; Greening, C; Hards, K; Harold, LK; Jackson, CJ; Lee, BM; Mohamed, AE; Nuermberger, EL; Pidot, SJ; Stinear, TP; Taylor, MC; West, NP	1
de Jong, BC; Decroo, T; Lynen, L; Piubello, A; Van Deun, A	1
Bateson, A; Conradie, F; Crook, AM; Diacon, AH; Egizi, E; Everitt, D; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Moreira, J; Ngubane, N; Olugbosi, M; Spigelman, M; Timm, J; Van Niekerk, C; Wills, GH	1
Farhat, M; Kadura, S; King, N; Köser, CU; Nakhoul, M; Theron, G; Zhu, H	1
Bigelow, KM; Chang, YS; Dooley, KE; Nuermberger, EL; Tasneen, R	1
Hussar, DA	1
Bashiri, G; Ioerger, T; Lanoix, JP; Lee, J; Li, SY; Nuermberger, E; Rifat, D; Sacchettini, J; Shah, K	1
Everitt, D; Li, M; Mendel, CM; Nedelman, JR; Salinger, DH; Spigelman, M; Subramoney, V; Wade, K; Woolson, R	1
Chopra, S; Dasgupta, A; Thakare, R	1
El-Amin, W; Everitt, D; Li, M; Makhene, MK; Nedelman, J; Osborn, B; Saviolakis, GA; Yang, TJ	1
Castel, S; Dawson, R; Dooley, KE; Ignatius, EH; Joubert, A; Kellermann, T; Malo, A; Norman, J; Wiesner, L	1
Nambiar, S; Schumann, K; Walinsky, S	1
Begum, A; Fatima, N; Heba, SF; Parveen, U; Rafi, R; Sultana, S	1
Biswas, S; Deb, U	1
Pregnolato, M; Taccani, M; Terreni, M	1
Abdel-Rahman, SM; Mirzayev, F; Stancil, SL	1
de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A	1
Ang, CW; Blaskovich, MAT; Cooper, MA; Popat, A; Qu, Z; Tan, L; West, NP	1
Campino, S; Clark, TG; Gomes, P; Gómez-González, PJ; Hibberd, ML; Napier, G; Perdigao, J; Phelan, JE; Portugal, I; Puyen, ZM; Santos-Lazaro, D; Viveiros, M	1
He, W; Li, F; Shen, C; Wang, S; Wang, Y; Xia, H; Zhao, B; Zhao, Y; Zheng, H	1
Avaliani, Z; Conradie, F; Cook-Scalise, S; Everitt, D; Garfin, AMC; Gomez, GB; Juneja, S; Kiria, N; Lomtadze, N; Malhotra, S; Ndjeka, N; Siapka, M; Spigelman, M; Vassall, A	1
Howell, P; Mvuna, N; Olugbosi, M; Upton, C	1
Almoslem, M; Drusano, GL; Duncanson, B; Kim, S; Louie, A; Myrick, J; Neely, M; Nole, J; Peloquin, CA; Scanga, CA; Schmidt, S; Yamada, W	1
Cook-Scalise, S; Edo, P; Gebhard, A; Juneja, S; Kadyrov, A; Lawanson, A; Malhotra, S; Mambetova, E; Mulder, C; Pambudi, I; Rupert, S; Setiawan, E; Sohn, H; Sugiharto, J; Useni, S; van den Hof, S	1
Bax, HI; De Steenwinkel, JEM; Lenaerts, A; Mudde, SE; Upton, AM	1
Andres, S; Bateson, A; Borroni, E; Cirillo, DM; Dippenaar, A; Feuerriegel, S; Ghodousi, A; Groenheit, R; Kohl, TA; Köser, CU; Kranzer, K; Machado, D; Maurer, FP; McHugh, TD; Merker, M; Niemann, S; Ortiz Canseco, J; Sirgel, F; Sun, E; Timm, J; Toro, JC; Utpatel, C; Viveiros, M; Warren, RM; Werngren, J; Wijkander, M; Witney, AA	1
Shaheer, M; Singh, R; Sobhia, ME	1
Hui, AM; Li, K; Liu, Y; Lu, Z; Tan, Y; Wei, G; Yang, B	1
Betteridge, M; Boekelheide, K; Everitt, D; Nedelman, J; Olugbosi, M; Smith, E; Spigelman, M; Sun, E	1
Alffenaar, J; Burke, A; Denholm, J	1
Devaleenal, B; Mandal, S; Mattoo, S; Padmapriyadarsini, C; Parmar, M; Ponnuraja, C; Ramraj, B; Singla, R	1
Bagdasaryan, TR; Bateson, A; Borisov, S; Conradie, F; Crook, AM; Egizi, E; Everitt, D; Fabiane, SM; Foraida, S; Holsta, A; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Mikiashvili, L; Ngubane, N; Olugbosi, M; Samoilova, A; Skornykova, S; Spigelman, M; Sun, E; Timm, J; Tudor, E; Tweed, CD; Variava, E; Wills, GH; Yablonskiy, P	1
Ashkin, D; Goswami, ND; Haley, CA	1
Juturu, RR; Surapuraju, PKR	1
Bekele, F; Fekadu, G; Fetensa, G; Tolossa, T; Turi, E	1
Groenheit, R; Grönfors Seeth, C; Karlsson Lindsjö, O; Mansjö, M; Werngren, J	1
Barnes, G; Dawson, R; Dooley, KE; Dorman, SE; Friedman, A; Gupte, N; Hendricks, B; Ignatius, EH; Narunsky, K; Smit, T; Whitelaw, C	1
Bahr, M; Brosnan, MK; Chen, X; Dannals, RF; De Jesus, P; Erice, C; Flavahan, K; Holt, DP; Jain, SK; Kim, J; Lodge, MA; Mota, F; Ordonez, AA; Peloquin, CA; Ruiz-Bedoya, CA; Tucker, EW	1
Nahid, P; Velásquez, GE	1
Aarnoutse, R; Andres, S; Choong, E; Decosterd, LA; Dreyer, V; John, A; Kalsdorf, B; Koehler, N; König, C; Krieger, D; Kuhns, M; Lange, C; Maurer, FP; Merker, M; Niemann, S; Peloquin, CA; Sanchez Carballo, PM; Schaub, D; Schön, T; Schönfeld, N; Verougstraete, N; Verstraete, AG; Werngren, J; Wicha, SG; Zur Wiesch, PA	1
Guo, T; Mehta, K; van der Graaf, PH; van Hasselt, JGC	1
Betoudji, F; Converse, PJ; Fotouhi, N; Lee, J; Li, SY; Mdluli, K; Nuermberger, EL; Upton, A	1
Abrahams, KA; Bashiri, G; Batt, SM; Besra, GS; Gurcha, SS; Veerapen, N	1
Alffenaar, JC; Anthony, RM; Nguyen, QH; Nguyen, TNT; Nguyen, TVA; Vu, DH	1
Abdalla, BJ; Abramovitch, RB; Albrecht, VJ; Eke, IE; Haiderer, ER; Murdoch, HM; Williams, JT	1
Ahrenstorf, G; Friesen, I; Joean, O; Kuhns, M; Picksak, G; Ringshausen, FC; Trauth, J; Welte, T	1

Reviews

22 review(s) available for azomycin and pa 824

Article	Year
[Anti-tuberculosis drugs]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61 Suppl 2 Topics: 4-Quinolones; Anti-Infective Agents; Antitubercular Agents; Chlorpromazine; Drug Delivery Systems; Drug Design; Drug Resistance, Multiple, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Rifamycins	2003
Advances in the treatment of tuberculosis. Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:5 Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2007
PA-824. Tuberculosis (Edinburgh, Scotland), 2008, Volume: 88, Issue:2 Topics: Animals; Antitubercular Agents; Humans; Nitroimidazoles; Treatment Outcome; Tuberculosis	2008
New anti-tuberculosis drugs with novel mechanisms of action. Current medicinal chemistry, 2008, Volume: 15, Issue:19 Topics: Adamantane; Animals; Antitubercular Agents; Diarylquinolines; Drug Design; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Quinolines; Structure-Activity Relationship; Tuberculosis, Pulmonary	2008
The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies. Future medicinal chemistry, 2010, Volume: 2, Issue:8 Topics: Animals; Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Structure-Activity Relationship; Tuberculosis	2010
PA-824 , moxifloxacin and pyrazinamide combination therapy for tuberculosis. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:7 Topics: Animals; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Molecular Structure; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis, Pulmonary	2013
Tuberculosis: clinical trials and new drug regimens. Current opinion in pulmonary medicine, 2014, Volume: 20, Issue:3 Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant	2014
Managing multidrug-resistant tuberculosis in children: review of recent developments. Current opinion in infectious diseases, 2014, Volume: 27, Issue:3 Topics: Antitubercular Agents; Child; Child, Preschool; Directly Observed Therapy; Drug Administration Schedule; Ethionamide; Fluoroquinolones; Humans; Infant; Moxifloxacin; Nitroimidazoles; Practice Guidelines as Topic; Prevalence; Pyrazinamide; Risk Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2014
Novel drugs against tuberculosis: a clinician's perspective. The European respiratory journal, 2015, Volume: 45, Issue:4 Topics: Adamantane; Antitubercular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diarylquinolines; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Female; Follow-Up Studies; Humans; Male; Nitroimidazoles; Oxazoles; Oxazolidinones; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2015
ADVANCES IN PHARMACOTHERAPY OF TUBERCULOSIS. Acta poloniae pharmaceutica, 2017, Volume: 74, Issue:1 Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Humans; Nitroimidazoles; Oxazolidinones; Tuberculosis, Multidrug-Resistant	2017
New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis. Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia, 2018, Volume: 44, Issue:2 Topics: Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Repositioning; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Oxazoles	2018
New drugs to treat difficult tuberculous and nontuberculous mycobacterial pulmonary disease. Current opinion in pulmonary medicine, 2019, Volume: 25, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Clofazimine; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Liposomes; Lung Diseases; Microbial Sensitivity Tests; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Oxazoles	2019
The Lancet Respiratory Medicine Commission: 2019 update: epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant and incurable tuberculosis. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:9 Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Humans; Linezolid; Nitroimidazoles; Oxazoles; Periodicals as Topic; Pulmonary Medicine; Societies, Medical; Tuberculosis; Tuberculosis, Multidrug-Resistant	2019
Pretomanid: First Approval. Drugs, 2019, Volume: 79, Issue:16 Topics: Anti-Bacterial Agents; Antifungal Agents; Drug Approval; Humans; Nitroimidazoles; Tuberculosis; United States	2019
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. The Journal of antimicrobial chemotherapy, 2020, 08-01, Volume: 75, Issue:8 Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pharmaceutical Preparations; Tuberculosis, Multidrug-Resistant	2020
Pretomanid: A novel therapeutic paradigm for treatment of drug resistant tuberculosis. The Indian journal of tuberculosis, 2021, Volume: 68, Issue:1 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant	2021
Pretomanid: The latest USFDA-approved anti-tuberculosis drug. The Indian journal of tuberculosis, 2021, Volume: 68, Issue:2 Topics: Antitubercular Agents; Drug Approval; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; United States; United States Food and Drug Administration	2021
New Antibiotics for Multidrug-Resistant Bacterial Strains: Latest Research Developments and Future Perspectives. Molecules (Basel, Switzerland), 2021, May-02, Volume: 26, Issue:9 Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Boronic Acids; Cefiderocol; Cephalosporins; Chemistry, Pharmaceutical; Clostridioides difficile; Clostridium Infections; Drug Design; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Meropenem; Neisseria gonorrhoeae; Nitroimidazoles; Sisomicin; Tetracyclines	2021
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date. Drug design, development and therapy, 2021, Volume: 15 Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant	2021
Pretomanid for tuberculosis: a systematic review. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2022, Volume: 28, Issue:1 Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Pretomanid development and its clinical roles in treating tuberculosis. Journal of global antimicrobial resistance, 2022, Volume: 31 Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Pretomanid resistance: An update on emergence, mechanisms and relevance for clinical practice. International journal of antimicrobial agents, 2023, Volume: 62, Issue:4 Topics: Animals; Antitubercular Agents; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023

Trials

19 trial(s) available for azomycin and pa 824

Article	Year
Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Adult; Antitubercular Agents; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nitroimidazoles; Young Adult	2009
Assessment of the effects of the nitroimidazo-oxazine PA-824 on renal function in healthy subjects. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:9 Topics: Adult; Antitubercular Agents; Blood Urea Nitrogen; Creatinine; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Nitroimidazoles; Renal Plasma Flow, Effective; Young Adult	2009
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:8 Topics: Adult; Antitubercular Agents; Colony Count, Microbial; Culture Media; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mycobacterium tuberculosis; Nitroimidazoles; Sputum; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult	2010
Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult	2012
14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet (London, England), 2012, Sep-15, Volume: 380, Issue:9846 Topics: Adult; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Male; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Prospective Studies; Pyrazinamide; Quinolines; Sputum; Tuberculosis, Pulmonary; Young Adult	2012
Evaluation of pharmacokinetic interaction between PA-824 and midazolam in healthy adult subjects. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8 Topics: Adolescent; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Midazolam; Middle Aged; Nitroimidazoles; Time Factors; Young Adult	2013
Effect of a high-calorie, high-fat meal on the bioavailability and pharmacokinetics of PA-824 in healthy adult subjects. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11 Topics: Administration, Oral; Adult; Antitubercular Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Dietary Fats; Drug Administration Schedule; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Humans; Male; Middle Aged; Nitroimidazoles	2013
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:9 Topics: Adult; Alkynes; Antitubercular Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Nitroimidazoles; Pharmacogenetics; Rifampin; Ritonavir; Young Adult	2014
Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. American journal of respiratory and critical care medicine, 2015, Apr-15, Volume: 191, Issue:8 Topics: Adult; Antitubercular Agents; Clofazimine; Diarylquinolines; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Nitroimidazoles; Pyrazinamide; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant	2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2015
Long-Term Effects on QT Prolongation of Pretomanid Alone and in Combinations in Patients with Tuberculosis. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10 Topics: Antitubercular Agents; Computer Simulation; Diarylquinolines; Double-Blind Method; Drug Therapy, Combination; Electrocardiography; Heart Rate; Humans; Linezolid; Long QT Syndrome; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2019
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda	2019
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis. The New England journal of medicine, 2020, 03-05, Volume: 382, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Antitubercular Agents; Bacterial Load; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Female; Humans; Intention to Treat Analysis; Linezolid; Male; Middle Aged; Mycobacterium tuberculosis; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult	2020
Phase 1 Study of the Effects of the Tuberculosis Treatment Pretomanid, Alone and in Combination With Moxifloxacin, on the QTc Interval in Healthy Volunteers. Clinical pharmacology in drug development, 2021, Volume: 10, Issue:6 Topics: Adolescent; Adult; Antitubercular Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Electrocardiography; Female; Humans; Long QT Syndrome; Male; Middle Aged; Moxifloxacin; Nitroimidazoles; Young Adult	2021
Pretomanid dose selection for pulmonary tuberculosis: An application of multi-objective optimization to dosage regimen design. CPT: pharmacometrics & systems pharmacology, 2021, Volume: 10, Issue:3 Topics: Adult; Antitubercular Agents; Colony-Forming Units Assay; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Nitroimidazoles; Safety; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2021
Safety and pharmacokinetic profile of pretomanid in healthy Chinese adults: Results of a phase I single dose escalation study. Pulmonary pharmacology & therapeutics, 2022, Volume: 73-74 Topics: Adult; Area Under Curve; Asian People; China; Dose-Response Relationship, Drug; Double-Blind Method; Female; Healthy Volunteers; Humans; Hyperbilirubinemia; Male; Nitroimidazoles; Young Adult	2022
Randomised trial to evaluate the effectiveness and safety of varying doses of linezolid with bedaquiline and pretomanid in adults with pre-extensively drug-resistant or treatment intolerant/non-responsive multidrug-resistant pulmonary tuberculosis: study BMJ open, 2022, 08-29, Volume: 12, Issue:8 Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Randomized Controlled Trials as Topic; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis. The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9 Topics: Aminoglycosides; Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Rifampin; Risk Assessment; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant	2022
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results. American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7 Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary	2023

Other Studies

137 other study(ies) available for azomycin and pa 824

Article	Year
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 2000, Jun-22, Volume: 405, Issue:6789 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Resistance, Microbial; Drug Resistance, Multiple; Guinea Pigs; Lipids; Metronidazole; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Tuberculosis	2000
Use of transposon Tn5367 mutagenesis and a nitroimidazopyran-based selection system to demonstrate a requirement for fbiA and fbiB in coenzyme F(420) biosynthesis by Mycobacterium bovis BCG. Journal of bacteriology, 2001, Volume: 183, Issue:24 Topics: Antitubercular Agents; Bacterial Proteins; Coenzymes; DNA Transposable Elements; Drug Resistance, Bacterial; Enzymes; Genes, Bacterial; Genetic Complementation Test; Multigene Family; Mutagenesis, Insertional; Mycobacterium bovis; Nitroimidazoles; Operon; Riboflavin; Sequence Analysis, DNA; Transcription, Genetic	2001
Demonstration that fbiC is required by Mycobacterium bovis BCG for coenzyme F(420) and FO biosynthesis. Journal of bacteriology, 2002, Volume: 184, Issue:9 Topics: Cloning, Molecular; DNA Transposable Elements; Escherichia coli; Genes, Bacterial; Genetic Complementation Test; Histidine; Molecular Sequence Data; Multigene Family; Mutagenesis, Insertional; Mycobacterium bovis; Nitroimidazoles; Riboflavin	2002
Tuberculosis: new drug class investigated through public-private partnership. AIDS treatment news, 2000, Jul-07, Issue:346 Topics: Antitubercular Agents; Cooperative Behavior; Humans; Nitroimidazoles; Private Sector; Public Sector; Tuberculosis	2000
Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:6 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Random Allocation; Tuberculosis, Pulmonary	2005
Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrobial agents and chemotherapy, 2005, Volume: 49, Issue:6 Topics: Animals; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Humans; Lung; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Specific Pathogen-Free Organisms; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2005
New tuberculosis drug enters human trials. The Lancet. Infectious diseases, 2005, Volume: 5, Issue:8 Topics: Antitubercular Agents; Clinical Trials as Topic; Humans; Nitroimidazoles; Tuberculosis	2005
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America, 2006, Jan-10, Volume: 103, Issue:2 Topics: Bacterial Proteins; DNA Transposable Elements; Drug Resistance, Bacterial; Genome, Bacterial; Glucosephosphate Dehydrogenase; Molecular Sequence Data; Molecular Structure; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Phenotype	2006
NIAID researchers make key discovery in development of TB drug candidate. Journal of investigative medicine : the official publication of the American Federation for Clinical Research, 2006, Volume: 54, Issue:2 Topics: Antitubercular Agents; Drug Design; Drug Resistance, Bacterial; Mycobacterium tuberculosis; National Institutes of Health (U.S.); Nitroimidazoles; United States	2006
Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:4 Topics: Acetamides; Animals; Anti-Infective Agents; Aza Compounds; Diarylquinolines; Female; Fluoroquinolones; Leprosy; Linezolid; Mice; Moxifloxacin; Mycobacterium leprae; Nitroimidazoles; Oxazolidinones; Quinolines	2006
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:6 Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors	2006
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:8 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Rifampin; Secondary Prevention; Time Factors; Tuberculosis, Pulmonary	2006
Mycobacterium leprae is naturally resistant to PA-824. Antimicrobial agents and chemotherapy, 2006, Volume: 50, Issue:10 Topics: Animals; Culture Media; Disease Models, Animal; Drug Resistance, Bacterial; Leprosy; Macrophages, Peritoneal; Mice; Mice, Inbred BALB C; Mice, Nude; Microbial Sensitivity Tests; Mycobacterium leprae; Nitroimidazoles	2006
NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis. International journal of antimicrobial agents, 2007, Volume: 29, Issue:6 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Imidazoles; Inhibitory Concentration 50; Mycobacterium tuberculosis; Nitroimidazoles; Prodrugs; Quinolines; Time Factors; Vero Cells	2007
Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2008, Volume: 12, Issue:1 Topics: Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Time Factors	2008
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Lung; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis, Pulmonary	2008
Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824. Bioorganic & medicinal chemistry letters, 2008, Apr-01, Volume: 18, Issue:7 Topics: Antitubercular Agents; Crystallography, X-Ray; Drug Resistance, Bacterial; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Stereoisomerism; Structure-Activity Relationship	2008
Crystal structures of F420-dependent glucose-6-phosphate dehydrogenase FGD1 involved in the activation of the anti-tuberculosis drug candidate PA-824 reveal the basis of coenzyme and substrate binding. The Journal of biological chemistry, 2008, Jun-20, Volume: 283, Issue:25 Topics: Amino Acid Sequence; Antitubercular Agents; Crystallography, X-Ray; Glucosephosphate Dehydrogenase; Kinetics; Models, Chemical; Molecular Conformation; Molecular Sequence Data; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Protein Binding; Protein Conformation; Sequence Homology, Amino Acid; Substrate Specificity	2008
[Some new antitubercular agents]. Revue medicale suisse, 2008, Mar-19, Volume: 4, Issue:149 Topics: Acetamides; Antitubercular Agents; Diarylquinolines; Humans; Linezolid; Nitroimidazoles; Oxazoles; Oxazolidinones; Quinolines	2008
Intermediates in the reduction of the antituberculosis drug PA-824, (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine, in aqueous solution. Organic & biomolecular chemistry, 2008, Jun-07, Volume: 6, Issue:11 Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Magnetic Resonance Spectroscopy; Models, Molecular; Nitroimidazoles; Oxidation-Reduction; Solutions; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Water	2008
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2008, Volume: 52, Issue:10 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitroimidazoles; Pyrazinamide; Recurrence; Rifampin; Tuberculosis, Pulmonary	2008
Microbiology. An antibiotic mimics immunity. Science (New York, N.Y.), 2008, Nov-28, Volume: 322, Issue:5906 Topics: Anaerobiosis; Antitubercular Agents; Glucosephosphate Dehydrogenase; Humans; Mycobacterium tuberculosis; Nitric Oxide; Nitroimidazoles; Nitroreductases; Reactive Nitrogen Species; Riboflavin; Tuberculosis	2008
PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science (New York, N.Y.), 2008, Nov-28, Volume: 322, Issue:5906 Topics: Anaerobiosis; Antitubercular Agents; Glucosephosphate Dehydrogenase; Immunity, Innate; Mycobacterium tuberculosis; Nitric Oxide; Nitric Oxide Donors; Nitroimidazoles; Nitroreductases; Oxidation-Reduction; Prodrugs; Reactive Nitrogen Species; Riboflavin; Stereoisomerism	2008
Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2009, Feb-12, Volume: 52, Issue:3 Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxidation-Reduction; Vero Cells	2009
Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrobial agents and chemotherapy, 2009, Volume: 53, Issue:4 Topics: Administration, Inhalation; Aerosols; Animals; Antitubercular Agents; Guinea Pigs; Male; Nitroimidazoles; Powders	2009
Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2010, Jan-14, Volume: 53, Issue:1 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Evaluation, Preclinical; Mice; Mice, Inbred BALB C; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Stereoisomerism; Structure-Activity Relationship	2010
Release of nitrite from the antitubercular nitroimidazole drug PA-824 and analogues upon one-electron reduction in protic, non-aqueous solvent. Organic & biomolecular chemistry, 2010, Jan-21, Volume: 8, Issue:2 Topics: Aerobiosis; Antitubercular Agents; Electron Transport; Hypoxia; Mass Spectrometry; Mycobacterium tuberculosis; Nitriles; Nitrites; Nitrobenzenes; Nitroimidazoles; Pulse Radiolysis; Reactive Nitrogen Species; Solvents; Spectrophotometry, Ultraviolet; Water	2010
Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:4 Topics: Administration, Inhalation; Administration, Oral; Aerosols; Animals; Antitubercular Agents; Chemistry, Pharmaceutical; Colony Count, Microbial; Disease Models, Animal; Extensively Drug-Resistant Tuberculosis; Guinea Pigs; Humans; Latent Tuberculosis; Lung; Male; Nitroimidazoles; Particle Size; Powders; Spleen; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2010
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins	2010
A concise and convergent synthesis of PA-824. The Journal of organic chemistry, 2010, Nov-05, Volume: 75, Issue:21 Topics: Antitubercular Agents; Drug Resistance, Multiple; Hydrolysis; Kinetics; Nitroimidazoles; Stereoisomerism	2010
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:1 Topics: Animals; Antitubercular Agents; Female; Humans; Mice; Nitroimidazoles; Tuberculosis	2011
Comparative bioactivation of the novel anti-tuberculosis agent PA-824 in Mycobacteria and a subcellular fraction of human liver. British journal of pharmacology, 2011, Volume: 162, Issue:1 Topics: Antitubercular Agents; Base Sequence; Biotransformation; DNA Primers; Humans; Liver; Mass Spectrometry; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Subcellular Fractions	2011
Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2010, Dec-09, Volume: 53, Issue:23 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred BALB C; Nitroimidazoles; Oxazines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tuberculosis	2010
Half-century-old TB drugs get a facelift in new cocktails. Nature medicine, 2010, Volume: 16, Issue:12 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Discovery; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2010
The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824. Bioorganic & medicinal chemistry letters, 2011, Jan-15, Volume: 21, Issue:2 Topics: Antitubercular Agents; Electrochemistry; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxidation-Reduction; Tuberculosis	2011
Pharmacophore modeling and density functional theory analysis for a series of nitroimidazole compounds with antitubercular activity. Chemical biology & drug design, 2011, Volume: 78, Issue:3 Topics: Antitubercular Agents; Drug Design; Humans; Models, Biological; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Quantitative Structure-Activity Relationship; Quantum Theory; Tuberculosis	2011
Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824). Journal of medicinal chemistry, 2011, Aug-25, Volume: 54, Issue:16 Topics: Animals; Antitubercular Agents; Bacterial Proteins; Drug Evaluation, Preclinical; Humans; Kinetics; Metabolic Clearance Rate; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Prodrugs; Structure-Activity Relationship; Substrate Specificity; Tuberculosis	2011
Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2011, Oct-13, Volume: 54, Issue:19 Topics: Acute Disease; Animals; Antitubercular Agents; Chronic Disease; Ethers; Humans; In Vitro Techniques; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Stereoisomerism; Structure-Activity Relationship; Tuberculosis, Pulmonary	2011
The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future medicinal chemistry, 2011, Volume: 3, Issue:10 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Diarylquinolines; Drug Evaluation, Preclinical; Fluoroquinolones; Humans; Models, Organizational; Moxifloxacin; Nitroimidazoles; Quinolines; Tuberculosis	2011
Integrative analysis of transcriptome and genome indicates two potential genomic islands are associated with pathogenesis of Mycobacterium tuberculosis. Gene, 2011, Dec-01, Volume: 489, Issue:1 Topics: Base Sequence; Down-Regulation; Gene Expression Profiling; Genomic Islands; Lipids; Molecular Sequence Data; Mycobacterium tuberculosis; Nitroimidazoles	2011
Impact of Fgd1 and ddn diversity in Mycobacterium tuberculosis complex on in vitro susceptibility to PA-824. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12 Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Genetic Variation; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Polymorphism, Single Nucleotide; Sequence Analysis, DNA	2011
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2011, Volume: 55, Issue:12 Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Secondary Prevention; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2011
Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles. The FEBS journal, 2012, Volume: 279, Issue:1 Topics: Antitubercular Agents; Cloning, Molecular; Flavins; Kinetics; Mycobacterium tuberculosis; Nitric Oxide; Nitroimidazoles; Nitroreductases; Oxazoles; Protein Conformation; Stereoisomerism; Structure-Activity Relationship; Substrate Specificity	2012
Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2012, Jan-12, Volume: 55, Issue:1 Topics: Acute Disease; Amides; Animals; Antitubercular Agents; Biological Availability; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Carbamates; Chronic Disease; Dogs; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Models, Molecular; Mycobacterium tuberculosis; Nitroimidazoles; Piperazines; Rats; Solubility; Stereoisomerism; Structure-Activity Relationship; Tuberculosis, Pulmonary; Urea	2012
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. The Journal of infectious diseases, 2012, Feb-15, Volume: 205, Issue:4 Topics: Animals; Antitubercular Agents; Aza Compounds; Disease Models, Animal; Fluoroquinolones; Gene Expression Profiling; Genes, Bacterial; Granuloma; Hypoxia; Immunohistochemistry; Male; Mice; Mice, Inbred C3H; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Positron-Emission Tomography; Pyrazinamide; Quinolines; Treatment Outcome; Tuberculosis	2012
Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PloS one, 2012, Volume: 7, Issue:1 Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Monitoring; Drug Therapy, Combination; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Quinolines; Reproducibility of Results; Time Factors	2012
Trial tests new combination of drugs to treat tuberculosis. BMJ (Clinical research ed.), 2012, Mar-20, Volume: 344 Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Humans; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Research Support as Topic; Tuberculosis; United States	2012
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:6 Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant	2012
In vitro activities of the new antitubercular agents PA-824 and BTZ043 against Nocardia brasiliensis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:7 Topics: Antitubercular Agents; Microbial Sensitivity Tests; Nitroimidazoles; Nocardia	2012
New drug combination for TB is tested in unique trial. BMJ (Clinical research ed.), 2012, Jul-25, Volume: 345 Topics: Antitubercular Agents; Aza Compounds; Clinical Trials as Topic; Drug Combinations; Fluoroquinolones; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Quinolines; Tuberculosis	2012
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:11 Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins	2012
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:8 Topics: Animals; Antitubercular Agents; Area Under Curve; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Guinea Pigs; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Organ Size; Pyrazinamide; Recurrence; Rifamycins; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2013
Bactericidal activity of PA-824 against Mycobacterium tuberculosis under anaerobic conditions and computational analysis of its novel analogues against mutant Ddn receptor. BMC microbiology, 2013, Oct-01, Volume: 13 Topics: Anaerobiosis; Antitubercular Agents; Colony Count, Microbial; Drug Resistance, Bacterial; Humans; Microbial Viability; Molecular Docking Simulation; Mutant Proteins; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases	2013
Rv0132c of Mycobacterium tuberculosis encodes a coenzyme F420-dependent hydroxymycolic acid dehydrogenase. PloS one, 2013, Volume: 8, Issue:12 Topics: Amino Acid Sequence; Antitubercular Agents; Bacterial Proteins; Cell Wall; Gene Expression; Humans; Kinetics; Molecular Sequence Data; Mycobacterium tuberculosis; Mycolic Acids; Nitroimidazoles; Oxidoreductases; Riboflavin; Sequence Alignment; Sequence Homology, Amino Acid; Substrate Specificity	2013
LC-MS/MS method for the simultaneous determination of PA-824, moxifloxacin and pyrazinamide in rat plasma and its application to pharmacokinetic study. Journal of pharmaceutical and biomedical analysis, 2014, Volume: 97 Topics: Animals; Chromatography, Liquid; Drug Interactions; Fluoroquinolones; Limit of Detection; Metronidazole; Moxifloxacin; Nitroimidazoles; Plasma; Pyrazinamide; Rats; Tandem Mass Spectrometry	2014
Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis. PloS one, 2014, Volume: 9, Issue:8 Topics: Animals; Caco-2 Cells; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Retrospective Studies; Tuberculosis	2014
PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice. International journal of antimicrobial agents, 2014, Volume: 44, Issue:6 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Isoniazid; Latent Tuberculosis; Lung; Mice; Mice, Inbred C3H; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin	2014
In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Animals; Antitubercular Agents; Caco-2 Cells; Cell Line, Tumor; Disease Models, Animal; Drug Interactions; Drug Resistance, Bacterial; Female; Humans; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Tuberculosis	2015
Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1 Topics: Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Oxazoles; Pyrazinamide; Random Allocation; Tuberculosis	2015
A novel molecule with notable activity against multi-drug resistant tuberculosis. Bioorganic & medicinal chemistry letters, 2015, Mar-15, Volume: 25, Issue:6 Topics: Antitubercular Agents; Cytochrome P-450 Enzyme System; Drug Design; Drug Synergism; Glucuronosyltransferase; Half-Life; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Piperazines; Pyridones; Tuberculosis, Multidrug-Resistant	2015
Synthesis and structure-activity relationships for extended side chain analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). Journal of medicinal chemistry, 2015, Apr-09, Volume: 58, Issue:7 Topics: Administration, Oral; Animals; Antitubercular Agents; Biological Availability; Chemistry Techniques, Synthetic; Chronic Disease; Disease Models, Animal; Humans; Male; Mice, Inbred BALB C; Mice, Inbred Strains; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rats, Sprague-Dawley; Structure-Activity Relationship; Tuberculosis	2015
New effective antituberculosis regimens. Lancet (London, England), 2015, May-02, Volume: 385, Issue:9979 Topics: Antitubercular Agents; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2015
Determination of the antitubercular drug PA-824 in rat plasma, lung and brain tissues by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, Apr-15, Volume: 988 Topics: Animals; Antitubercular Agents; Brain Chemistry; Chromatography, Liquid; Drug Stability; Female; Linear Models; Lung; Nitroimidazoles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry	2015
Structural insights of PA-824 derivatives: ligand-based 3D-QSAR study and design of novel PA824 derivatives as anti-tubercular agents. Journal of receptor and signal transduction research, 2015, Volume: 35, Issue:5 Topics: Antitubercular Agents; Binding Sites; Drug Design; Models, Chemical; Molecular Conformation; Molecular Docking Simulation; Nitroimidazoles; Quantitative Structure-Activity Relationship	2015
Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:9 Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Polymorphism, Genetic; Protein Structure, Secondary	2015
Synthesis and anti-tubercular activity of 2-nitroimidazooxazines with modification at the C-7 position as PA-824 analogs. Bioorganic & medicinal chemistry letters, 2015, Sep-01, Volume: 25, Issue:17 Topics: Antitubercular Agents; Chemistry Techniques, Synthetic; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Structure-Activity Relationship	2015
Tissue distribution of pretomanid in rat brain via mass spectrometry imaging. Xenobiotica; the fate of foreign compounds in biological systems, 2016, Volume: 46, Issue:3 Topics: Animals; Antitubercular Agents; Blood-Brain Barrier; Brain; Female; Nitroimidazoles; Prodrugs; Rats; Rats, Sprague-Dawley; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution	2016
Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:10 Topics: Agar; Antitubercular Agents; Biological Assay; Charcoal; Colony Count, Microbial; Coloring Agents; Diarylquinolines; Fluorometry; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazines; Xanthenes	2015
glpx Gene in Mycobacterium tuberculosis Is Required for In Vitro Gluconeogenic Growth and In Vivo Survival. PloS one, 2015, Volume: 10, Issue:9 Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Carbon; Fatty Acids; Fructose-Bisphosphatase; Gene Deletion; Genes, Bacterial; Gluconeogenesis; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Mycobacterium tuberculosis; Nitroimidazoles; Stress, Physiological; Tuberculosis	2015
Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2016, Volume: 60, Issue:1 Topics: Animals; Antitubercular Agents; Bacterial Load; Diarylquinolines; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Synergism; Female; Linezolid; Lung; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Organophosphates; Oxazoles; Oxazolidinones; Pyrazinamide; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary	2016
Pharmacokinetics and tissue distribution study of PA-824 in rats by LC-MS/MS. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2015, Dec-01, Volume: 1006 Topics: Administration, Oral; Animals; Chromatography, Liquid; Linear Models; Nitroimidazoles; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry; Tissue Distribution	2015
Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids. Bioorganic & medicinal chemistry letters, 2016, Jan-15, Volume: 26, Issue:2 Topics: Animals; Antitubercular Agents; Chronic Disease; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Tuberculosis	2016
Simultaneous HPLC assay for pretomanid (PA-824), moxifloxacin and pyrazinamide in an inhaler formulation for drug-resistant tuberculosis. Journal of pharmaceutical and biomedical analysis, 2017, Feb-20, Volume: 135 Topics: Administration, Inhalation; Antitubercular Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Compounding; Fluoroquinolones; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis, Multidrug-Resistant	2017
Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:3 Topics: Animals; Antimony; Antiprotozoal Agents; Cell Differentiation; Cell Line; Host-Pathogen Interactions; Humans; Inhibitory Concentration 50; Leishmania donovani; Macrophages; Mice; Mice, Knockout; Monocytes; Nitroimidazoles; Primary Cell Culture; Stereoisomerism; Tetradecanoylphorbol Acetate	2017
Easier cure for resistant TB. Science (New York, N.Y.), 2017, Feb-17, Volume: 355, Issue:6326 Topics: AIDS-Related Opportunistic Infections; Antitubercular Agents; Baltimore; Clinical Trials as Topic; Diarylquinolines; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; South Africa; Sputum; Treatment Outcome	2017
TB Alliance regimen development for multidrug-resistant tuberculosis. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2016, 12-01, Volume: 20, Issue:12 Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant	2016
6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]thiazoles: Facile synthesis and comparative appraisal against tuberculosis and neglected tropical diseases. Bioorganic & medicinal chemistry letters, 2017, 06-01, Volume: 27, Issue:11 Topics: Animals; Antitubercular Agents; Chagas Disease; Disease Models, Animal; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Structure-Activity Relationship; Thiazoles; Tuberculosis	2017
Biopharmaceutic parameters, pharmacokinetics, transport and CYP-mediated drug interactions of IIIM-017: A novel nitroimidazooxazole analogue with anti-tuberculosis activity. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2017, Aug-30, Volume: 106 Topics: Animals; Antitubercular Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Computer Simulation; Drug Interactions; Humans; Mice, Inbred BALB C; Microsomes, Liver; Nitroimidazoles; Oxazoles	2017
Bactericidal and Sterilizing Activity of a Novel Regimen with Bedaquiline, Pretomanid, Moxifloxacin, and Pyrazinamide in a Murine Model of Tuberculosis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:9 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis, Pulmonary	2017
Cordyceps sinensis promotes immune regulation and enhances bacteriostatic activity of PA-824 via IL-10 in Mycobacterium tuberculosis disease. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2017, Aug-07, Volume: 50, Issue:9 Topics: Animals; Anti-Bacterial Agents; Blotting, Western; Cordyceps; Disease Models, Animal; Flow Cytometry; Immunomodulation; Interleukin-10; Male; Mice; Mice, Inbred CBA; Mycobacterium tuberculosis; Nitroimidazoles; Real-Time Polymerase Chain Reaction; Tuberculosis, Pulmonary	2017
Dual Mechanism of Action of 5-Nitro-1,10-Phenanthroline against Mycobacterium tuberculosis. Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:11 Topics: Animals; Antitubercular Agents; Autophagy; Cell Line, Tumor; Disease Models, Animal; Escherichia coli; Female; Humans; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium bovis; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Phenanthrolines; Structure-Activity Relationship; THP-1 Cells; Tuberculosis, Multidrug-Resistant	2017
Assessment of a pretomanid analogue library for African trypanosomiasis: Hit-to-lead studies on 6-substituted 2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]thiazine 8-oxides. Bioorganic & medicinal chemistry letters, 2018, 01-15, Volume: 28, Issue:2 Topics: Administration, Oral; Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Mice; Molecular Structure; Nitroimidazoles; Small Molecule Libraries; Structure-Activity Relationship; Trypanosomiasis, African	2018
Novel Pyrimidines as Antitubercular Agents. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:3 Topics: Animals; Antitubercular Agents; Disease Models, Animal; Drug Design; Drug Stability; Female; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Pyrimidines; Solubility; Structure-Activity Relationship; Tuberculosis	2018
Drug-Drug Interactions Between PA-824 and Darunavir Based on Pharmacokinetics in Rats by LC-MS-MS. Journal of chromatographic science, 2018, Apr-01, Volume: 56, Issue:4 Topics: Animals; Chromatography, Liquid; Darunavir; Drug Interactions; Linear Models; Nitroimidazoles; Rats; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry	2018
Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions. Journal of medical microbiology, 2018, Volume: 67, Issue:3 Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Tolerance; Fluoroquinolones; Genetic Fitness; Genotype; Humans; Lipid Metabolism; Lipids; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin	2018
Untargeted metabolomics reveals a new mode of action of pretomanid (PA-824). Scientific reports, 2018, 03-23, Volume: 8, Issue:1 Topics: Antitubercular Agents; Gas Chromatography-Mass Spectrometry; Humans; Metabolic Networks and Pathways; Metabolome; Metabolomics; Mycobacterium Infections, Nontuberculous; Mycobacterium smegmatis; Nitroimidazoles	2018
Modeling and Simulation of Pretomanid Pharmacokinetics in Pulmonary Tuberculosis Patients. Antimicrobial agents and chemotherapy, 2018, Volume: 62, Issue:7 Topics: Adolescent; Adult; Antitubercular Agents; Female; Humans; Male; Middle Aged; Models, Theoretical; Monte Carlo Method; Nitroimidazoles; Tuberculosis, Pulmonary; Young Adult	2018
Enhanced brain penetration of pretomanid by intranasal administration of an oil-in-water nanoemulsion. Nanomedicine (London, England), 2018, Volume: 13, Issue:9 Topics: Administration, Intranasal; Animals; Brain; Chromatography, Liquid; Drug Delivery Systems; Emulsions; Male; Nanoparticles; Nitroimidazoles; Rats; Rats, Sprague-Dawley; Solid Phase Extraction; Tuberculosis, Meningeal	2018
Coenzyme F Journal of bacteriology, 2018, 12-01, Volume: 200, Issue:23 Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Glucosephosphate Dehydrogenase; Ligases; Methanobacteriaceae; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Polyglutamic Acid; Recombinant Proteins; Riboflavin; Tetrahydrofolates	2018
3D QSAR, Docking, Molecular Dynamics Simulations and MM-GBSA studies of Extended Side Chain of the Antitubercular Drug (6S) 2-Nitro-6- {[4-(trifluoromethoxy) benzyl] oxy}-6,7-dihydro-5H-imidazo[2,1-b] [1,3] oxazine. Infectious disorders drug targets, 2019, Volume: 19, Issue:2 Topics: Antitubercular Agents; Drug Development; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitroimidazoles; Quantitative Structure-Activity Relationship	2019
Rational design of coumarin derivatives as antituberculosis agents. Future medicinal chemistry, 2018, Volume: 10, Issue:20 Topics: Antitubercular Agents; Cell Survival; Coumarins; Drug Design; HeLa Cells; Humans; MCF-7 Cells; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitroimidazoles; Signal Transduction; Structure-Activity Relationship; THP-1 Cells	2018
Effect of Moxifloxacin plus Pretomanid against Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:1 Topics: Antitubercular Agents; Drug Combinations; Drug Interactions; Drug Resistance, Fungal; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles	2019
Design, Synthesis, and Biological Evaluation of 2-Nitroimidazopyrazin-one/-es with Antitubercular and Antiparasitic Activity. Journal of medicinal chemistry, 2018, 12-27, Volume: 61, Issue:24 Topics: Animals; Antiparasitic Agents; Antitubercular Agents; Caco-2 Cells; Drug Design; Drug Evaluation, Preclinical; Drug Stability; Entamoeba histolytica; Giardia lamblia; Humans; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Nitroimidazoles; Structure-Activity Relationship	2018
Comparison of in vitro activity of the nitroimidazoles delamanid and pretomanid against multidrug-resistant and extensively drug-resistant tuberculosis. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2019, Volume: 38, Issue:7 Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Multiple, Bacterial; Extensively Drug-Resistant Tuberculosis; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant	2019
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:7 Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Ion Concentration; Hypoxia; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis	2019
Chalcogen OCF ChemMedChem, 2019, 09-04, Volume: 14, Issue:17 Topics: Animals; Dogs; Humans; Hydrophobic and Hydrophilic Interactions; Madin Darby Canine Kidney Cells; Microsomes, Liver; Molecular Structure; Nitroimidazoles; Organoselenium Compounds; Riluzole; Sulfides	2019
Transcriptional profiling of a laboratory and clinical Mycobacterium tuberculosis strain suggests respiratory poisoning upon exposure to delamanid. Tuberculosis (Edinburgh, Scotland), 2019, Volume: 117 Topics: Aerobiosis; Antitubercular Agents; Cell Wall; Gene Expression Profiling; Gene Expression Regulation, Bacterial; Genome; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; RNA, Bacterial; Sequence Analysis, RNA	2019
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid. Antimicrobial agents and chemotherapy, 2019, Volume: 63, Issue:10 Topics: Antitubercular Agents; Biological Availability; Clinical Trials as Topic; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Lopinavir; Male; Nitroimidazoles; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2019
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations. BMC infectious diseases, 2019, Sep-09, Volume: 19, Issue:1 Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; Pyrazinamide; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant	2019
BPaL approved for multidrug-resistant tuberculosis. The Lancet. Infectious diseases, 2019, Volume: 19, Issue:10 Topics: Antitubercular Agents; Diarylquinolines; Drug Approval; Drug Therapy, Combination; Humans; Linezolid; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant	2019
Breakthrough in the treatment of drug-resistant tuberculosis. The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant	2019
Duration of pretomanid/moxifloxacin/pyrazinamide therapy compared with standard therapy based on time-to-extinction mathematics. The Journal of antimicrobial chemotherapy, 2020, 02-01, Volume: 75, Issue:2 Topics: Antitubercular Agents; Drug Therapy, Combination; Humans; Mathematics; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Tuberculosis	2020
Are pretomanid-containing regimens for tuberculosis a victory or a victory narrative? The Lancet. Respiratory medicine, 2019, Volume: 7, Issue:12 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2019
Pharmacophore modeling of pretomanid (PA-824) derivatives for antitubercular potency against replicating and non-replicating Journal of biomolecular structure & dynamics, 2021, Volume: 39, Issue:3 Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant	2021
Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering. PLoS pathogens, 2020, Volume: 16, Issue:2 Topics: Antitubercular Agents; Bacterial Proteins; Drug Resistance, Bacterial; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases; Oxazoles; Polymorphism, Genetic; Protein Engineering	2020
Tuberculosis treatment: one-shot approach or cascade of regimens? The Lancet. Respiratory medicine, 2020, Volume: 8, Issue:2 Topics: Diarylquinolines; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Pulmonary	2020
Preserved Efficacy and Reduced Toxicity with Intermittent Linezolid Dosing in Combination with Bedaquiline and Pretomanid in a Murine Tuberculosis Model. Antimicrobial agents and chemotherapy, 2020, 09-21, Volume: 64, Issue:10 Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant	2020
New drugs 2020, part 3. Nursing, 2020, Volume: 50, Issue:10 Topics: Aminophenols; Antibodies, Monoclonal, Humanized; Azabicyclo Compounds; Benzodioxoles; beta-Cyclodextrins; Cilastatin; Drug Approval; Drug Combinations; Ethinyl Estradiol; Genetic Vectors; Humans; Imipenem; Indoles; Nitroimidazoles; Pregnanolone; Pregnenediones; Pyrazoles; Pyridines; Pyrrolidines; Quinolones; Retinoids; United States; United States Food and Drug Administration	2020
Mutations in Antimicrobial agents and chemotherapy, 2020, 12-16, Volume: 65, Issue:1 Topics: Animals; Antitubercular Agents; Mice; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles	2020
An Exposure-Response Perspective on the Clinical Dose of Pretomanid. Antimicrobial agents and chemotherapy, 2020, 12-16, Volume: 65, Issue:1 Topics: Antitubercular Agents; Humans; Nitroimidazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant	2020
Pretomanid for the treatment of pulmonary tuberculosis. Drugs of today (Barcelona, Spain : 1998), 2020, Volume: 56, Issue:10 Topics: Adult; Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2020
A validated liquid chromatography tandem mass spectrometry assay for the analysis of pretomanid in plasma samples from pulmonary tuberculosis patients. Journal of pharmaceutical and biomedical analysis, 2021, Feb-20, Volume: 195 Topics: Adult; Chromatography, High Pressure Liquid; Chromatography, Liquid; Humans; Nitroimidazoles; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tuberculosis, Pulmonary	2021
FDA's Limited Population Pathway for Antibacterial and Antifungal Drugs. Clinical pharmacology and therapeutics, 2021, Volume: 109, Issue:4 Topics: Administration, Inhalation; Amikacin; Anti-Bacterial Agents; Antifungal Agents; Cross Infection; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; Extensively Drug-Resistant Tuberculosis; Humans; Liposomes; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Nitroimidazoles; Pneumonia, Bacterial; Pneumonia, Ventilator-Associated; Sisomicin; United States; United States Food and Drug Administration	2021
Mesoporous Silica Nanoparticles Improve Oral Delivery of Antitubercular Bicyclic Nitroimidazoles. ACS biomaterials science & engineering, 2022, Oct-10, Volume: 8, Issue:10 Topics: Amines; Animals; Antitubercular Agents; Drug Carriers; Mice; Nanoparticles; Nitroimidazoles; Organophosphonates; Silicon Dioxide	2022
Genetic diversity of candidate loci linked to Mycobacterium tuberculosis resistance to bedaquiline, delamanid and pretomanid. Scientific reports, 2021, 09-30, Volume: 11, Issue:1 Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Multiple, Bacterial; Humans; Mutation; Mycobacterium smegmatis; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant; Whole Genome Sequencing	2021
Antimicrobial agents and chemotherapy, 2022, 01-18, Volume: 66, Issue:1 Topics: Humans; Mycobacterium Infections, Nontuberculous; Nitroimidazoles; Nontuberculous Mycobacteria	2022
Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ open, 2021, 12-03, Volume: 11, Issue:12 Topics: Antitubercular Agents; Cost-Benefit Analysis; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Georgia; Humans; Linezolid; Nitroimidazoles; Philippines; South Africa; Tuberculosis, Multidrug-Resistant	2021
Sterile tuberculous granuloma in a patient with XDR-TB treated with bedaquiline, pretomanid and linezolid. BMJ case reports, 2021, Dec-07, Volume: 14, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Granuloma; Humans; Linezolid; Nitroimidazoles; Treatment Outcome; Tuberculosis, Multidrug-Resistant	2021
Evaluating the effect of clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid. International journal of antimicrobial agents, 2022, Volume: 59, Issue:2 Topics: Antitubercular Agents; Clofazimine; Diarylquinolines; Humans; Linezolid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant	2022
Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis. BMJ global health, 2022, Volume: 7, Issue:1 Topics: Antitubercular Agents; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Humans; Linezolid; Nitroimidazoles	2022
Delamanid or pretomanid? A Solomonic judgement! The Journal of antimicrobial chemotherapy, 2022, 03-31, Volume: 77, Issue:4 Topics: Antitubercular Agents; Diarylquinolines; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Tuberculosis, Multidrug-Resistant	2022
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid. The Journal of antimicrobial chemotherapy, 2022, 05-29, Volume: 77, Issue:6 Topics: Antitubercular Agents; Humans; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis	2022
Molecular dynamic assisted investigation on impact of mutations in deazaflavin dependent nitroreductase against pretomanid: a computational study. Journal of biomolecular structure & dynamics, 2023, Volume: 41, Issue:10 Topics: Antitubercular Agents; Ligands; Molecular Dynamics Simulation; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Nitroreductases	2023
Male reproductive hormones in patients treated with pretomanid. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022, 06-01, Volume: 26, Issue:6 Topics: Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Male; Nitroimidazoles; Testosterone; Tuberculosis, Multidrug-Resistant	2022
Evidence of safety for pretomanid and male reproductive health. The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2022, 06-01, Volume: 26, Issue:6 Topics: Antitubercular Agents; Humans; Male; Nitroimidazoles; Reproductive Health	2022
Pretomanid in the Treatment of Patients with Tuberculosis in the United States. The New England journal of medicine, 2022, 09-01, Volume: 387, Issue:9 Topics: Antitubercular Agents; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant; United States	2022
Development and validation of stability-indicating -HPLC method for the determination of related substances in novel nitroimidazole antituberculosis drug pretomanid: Robustness study by Design-Expert and application to stability studies. Biomedical chromatography : BMC, 2022, Volume: 36, Issue:12 Topics: Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Stability; Humans; Nitroimidazoles; Reproducibility of Results	2022
Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide. Antimicrobial agents and chemotherapy, 2022, 12-20, Volume: 66, Issue:12 Topics: Antitubercular Agents; Diarylquinolines; Humans; Nitroimidazoles; Pyrazinamide; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary	2022
The Antimicrobial agents and chemotherapy, 2022, 12-20, Volume: 66, Issue:12 Topics: Antitubercular Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Mutation; Mycobacterium tuberculosis; Nitroimidazoles; Tuberculosis, Multidrug-Resistant	2022
Dynamic Nature communications, 2022, 12-29, Volume: 13, Issue:1 Topics: Animals; Antitubercular Agents; Diarylquinolines; Disease Models, Animal; Humans; Linezolid; Mice; Mycobacterium tuberculosis; Nitroimidazoles; Rabbits; Tuberculosis, Meningeal; Tuberculosis, Multidrug-Resistant	2022
Promise and Peril of Pretomanid-Rifamycin Regimens for Drug-susceptible Tuberculosis. American journal of respiratory and critical care medicine, 2023, 04-01, Volume: 207, Issue:7 Topics: Antitubercular Agents; Humans; Nitroimidazoles; Rifamycins; Tuberculosis	2023
Pretomanid-resistant tuberculosis. The Journal of infection, 2023, Volume: 86, Issue:5 Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
Predictions of Bedaquiline and Pretomanid Target Attainment in Lung Lesions of Tuberculosis Patients using Translational Minimal Physiologically Based Pharmacokinetic Modeling. Clinical pharmacokinetics, 2023, Volume: 62, Issue:3 Topics: Animals; Antitubercular Agents; Humans; Lung; Mice; Nitroimidazoles; Pyrazinamide; Tuberculosis	2023
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model. Antimicrobial agents and chemotherapy, 2023, 04-18, Volume: 67, Issue:4 Topics: Animals; Antitubercular Agents; Diarylquinolines; Linezolid; Mice; Nitroimidazoles; Oxazolidinones; Tuberculosis; Tuberculosis, Multidrug-Resistant	2023
DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid. Nature communications, 2023, 06-28, Volume: 14, Issue:1 Topics: Alcohol Oxidoreductases; Antitubercular Agents; Cell Wall; Drug Resistance; Kinetics; Molecular Targeted Therapy; Mycobacterium tuberculosis; NAD; Nitroimidazoles; Prodrugs; Spectrophotometry	2023
Discovery and characterization of antimycobacterial nitro-containing compounds with distinct mechanisms of action and Antimicrobial agents and chemotherapy, 2023, 09-19, Volume: 67, Issue:9 Topics: Animals; Bacterial Load; Mice; Nitro Compounds; Nitrofurans; Nitroimidazoles	2023
The Implementation of a Pretomanid-Based Treatment Regimen for Multidrug-Resistant Tuberculosis: A Case Series. Deutsches Arzteblatt international, 2023, 09-22, Volume: 120, Issue:38 Topics: Antitubercular Agents; Humans; Nitroimidazoles; Tuberculosis, Multidrug-Resistant	2023